Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy recommendation. Analyst Price Forecast Suggests 17.14% Upside As of ...

Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam ...

It also relates to the early stage givosiran for acute hepatic porphyrias, Silence Therapeutics said. There is no suggestion that Alnylam and The Medicines Company acquired intellectual property ...

MicroRNAs are smaller than the small interfering RNA (siRNA) drugs now reaching the market, such as Alnylam’s Onpattro (patisiran), Givlaari (givosiran) and Oxlumo (lumasiran) for rare diseases.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare ...

– Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or B With or Without Inhibitors – CAMBRIDGE, Mass.--(BUSINESS ...

Department of Chemistry, University of Georgia, Athens, Georgia 30602, United States ...